infliximab vs SOR102
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
infliximab · Remicade
Marketed by Johnson & Johnson
NCT01585155 · Phase 3 · completed
No randomization, no blinding (masking: NONE), no control arm, single-group design with only 21 patients — this defaults to 'weak' per the design rules regardless of the favorable-looking remission percentages.
Next expected readout: December 2026 · NCT06839820 (registry estimate)
Reported efficacy
Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%
Result source: NCT01585155
SOR102
Developed by Sorriso Pharmaceuticals
NCT06080048 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Treatment Emergent Adverse Events following oral dosing". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Treatment Emergent Adverse Events following oral dosing (Up to 6 weeks in Part 3 or at the time of study discontinuation): First-in-human phase 1. Part 1 (healthy participants): treatment-emergent adverse events in 3/24 (13%) receiving SOR102 versus 2/8 (25%) receiving placebo. Part 2: no treatment-emergent adverse events in the 10 participants receiving twice-daily SOR102. Part 3 (ulcerative colitis patients): at least one adverse event in 7/16 (44%) treated with SOR102 and 3/6 (50%) receiving placebo. Rates of clinical response ranged from 29% to 67%, depending on the definition applied.
Result source: NCT06080048
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | infliximab | SOR102 |
|---|---|---|
| Clinical remission (induction) | —Trial running · NCT06614387 | —Not reported |
| Clinical remission (maintenance) | —Trial running · NCT06614387 | —Not reported |
| Clinical response (induction) | —Trial running · NCT06614387 | —Not reported |
| Endoscopic improvement (induction) | —Trial running · NCT06614387 | —Not reported |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT06614387 | —Not reported |
Clinical remission (induction)
- infliximab
- —Trial running · NCT06614387
- SOR102
- —Not reported
Clinical remission (maintenance)
- infliximab
- —Trial running · NCT06614387
- SOR102
- —Not reported
Clinical response (induction)
- infliximab
- —Trial running · NCT06614387
- SOR102
- —Not reported
Endoscopic improvement (induction)
- infliximab
- —Trial running · NCT06614387
- SOR102
- —Not reported
Corticosteroid-free remission (maintenance)
- infliximab
- —Trial running · NCT06614387
- SOR102
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SOR102: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. infliximab: 4 of 4 rows · SOR102: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | infliximab |
|---|---|
| Dropout rate | 23.8%a NCT01585155 · Phase 3 · monotherapy show 3 more results47.8%5 mg/kg every 12 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 18.2%5 mg/kg every 8 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 4.8%a NCT01585155 · Phase 3 · monotherapy show 3 more results26.1%5 mg/kg every 12 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 13.6%5 mg/kg every 8 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Serious AEs | 14.3%a NCT01585155 · Phase 3 · monotherapy show 3 more results21.7%5 mg/kg every 12 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 18.2%5 mg/kg every 8 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 0% NCT00791557 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a double stranded dna antibody positive 57.1% nasopharyngitis 33.3% acne 9.5% NCT01585155 · Phase 3 · monotherapy show 3 more results5 mg/kg every 12 weeks colitis ulcerative 65.2% upper respiratory tract infection 26.1% pain 17.4% NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5 mg/kg every 8 weeks colitis ulcerative 31.8% upper respiratory tract infection 31.8% fever 27.3% NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 bone marrow suppression 50% infection 50% infusion reaction 50% NCT00791557 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
infliximab
+ 31 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: infliximab's landscape · SOR102's landscape